logo

Aravive, Inc. (ARAV)



Trade ARAV now with
  Date
  Headline
6/24/2021 7:24:20 AM Aravive Says Positive Initial Results From Phase 1b Study Of AVB-500 With Cabozantinib In Clear Cell Renal Carcinoma
3/8/2021 7:11:18 AM Aravive Doses First Patient Dosed In Phase 1b/2 Clinical Trial Of AVB-500 In Clear Cell Renal Cell Carcinoma
11/19/2020 7:19:27 AM Aravive Receives Guidance From FDA On Phase 3 Trial Design For AVB-500
9/17/2020 7:07:12 AM Aravive Appoints Michael Rogers To Board
9/15/2020 7:27:26 AM Aravive Appoints Reshma Rangwala As Chief Medical Officer
4/9/2020 7:14:13 AM Aravive Announces Board Changes; Names Gail McIntyre CEO
5/10/2019 6:50:14 AM Wedbush Is Increasing Aravive, Inc. (ARAV) FY20 Estimate To -1.89 From -2.49
5/10/2019 6:49:58 AM Wedbush Is Increasing Aravive, Inc. (ARAV) Q4 20 Estimate To -0.43 From -0.56
5/10/2019 6:49:42 AM Wedbush Is Raising Aravive, Inc. (ARAV) Q3 20 Estimate To -0.52 From -0.69
5/10/2019 6:49:28 AM Wedbush Is Raising Aravive, Inc. (ARAV) Q2 20 Estimate To -0.48 From -0.64
5/10/2019 6:49:14 AM Wedbush Is Increasing Aravive, Inc. (ARAV) Q1 20 Estimate To -0.45 From -0.60
5/10/2019 6:48:54 AM Wedbush Is Increasing Aravive, Inc. (ARAV) FY19 Estimate To -1.91 From -2.87
5/10/2019 6:48:41 AM Wedbush Is Raising Aravive, Inc. (ARAV) Q4 19 Estimate To -0.42 From -0.57
5/10/2019 6:48:26 AM Wedbush Is Increasing Aravive, Inc. (ARAV) Q3 19 Estimate To -0.53 From -0.72
5/10/2019 6:48:10 AM Wedbush Is Raising Aravive, Inc. (ARAV) Q2 19 Estimate To -0.53 From -0.71
5/10/2019 6:47:24 AM Wedbush Reiterates Aravive, Inc. (ARAV) At Outperform With $14 Price Target